<DOC>
	<DOCNO>NCT02999737</DOCNO>
	<brief_summary>The injection autologous platelet rich plasma ( PRP ) relatively novel therapy , generate interest across wide variety medical specialty , orthopedics , dentistry , ophthalmology , dermatology . Several recently publish study demonstrate efficacy treat androgenetic alopecia ( aka male female pattern hair loss ) , vary treatment protocol , evidence-based data date guide dose parameter interval injection session . We propose single-center , single-blinded randomize pilot trial investigate beneficial number frequency ( 'schedule ' ) necessary PRP injection men woman androgenetic alopecia .</brief_summary>
	<brief_title>Comparing Different Platelet Rich Plasma ( PRP ) Treatment Regimens Management Androgenic Alopecia</brief_title>
	<detailed_description>Androgenetic alopecia common form hair loss , affect 50 % men 21 million woman US alone . Irrespective gender , bald know influence social interaction cause substantial emotional distress , especially begin lose hair early age . Topical minoxidil oral finasteride currently Food Drug Administration ( FDA ) -approved therapy androgenetic alopecia men , oral agent use off-label woman contraindicate pregnancy lactation . Response therapies varies , require continue use maintain benefit . Hair transplantation surgery permanent , yet costly , solution . All treatment carry risk undesirable side effect , demand innovative new therapeutic option . Autologous platelet rich plasma ( PRP ) injection novel therapy treatment pattern hair loss , study date evaluate different treatment protocols head-to-head . Hence , purpose study compare efficacy two different PRP treatment schedule ( frequency number injection session ) men woman androgenetic alopecia .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>Male female , age 1865 year AGA Completed sign consent form Norwood Hamilton stage IIV men Ludwig stage I2II1 woman In general good health Willing able attend study visit Willing maintain hair style hair care routine screen visit duration study Willing blood drawn Younger 18 year old 65 year Diagnosis alopecia areata nonAGA form hair loss Current skin disease , cut , abrasion scalp ( i.e . psoriasis , severe seborrheic dermatitis ) may limit data interpretation put subject increase risk Scalp infection Malignancy , except nonscalp nonmelanoma melanoma skin cancer , undergo chemotherapy radiation treatment Known history autoimmune thyroid disease , thyroid disorder , autoimmune disorder may interfere increase risk associated study treatment Pregnancy , anticipated pregnancy , breastfeed Tendency develop keloid History surgical correction hair loss scalp Use product , device , medication intend promote hair growth , except subject whose hair stable FDAapproved therapy ( i.e . oral finasteride and/or topical minoxidil ) 12 month Use antiandrogenic therapy ( i.e . spironolactone , flutamide , cyproterone , acetate , cimetidine ) within 90 day prior screen visit Current anticoagulant therapy , except subject take aspirin nonsteroidal antiinflammatory drug able interrupt medication seven day treatment subject take vitamin E overthecounter supplement able interrupt medication 14 day treatment Hereditary acquire hematologic/coagulation disorder include : platelet dysfunction syndrome thrombocytopenia ( count &lt; 150,000 platelets/Ul ) , hypofibrinogenemia , impaired coagulation , drepanocytosis ( sickle cell anemia ) Hemodynamic instability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Platelet Rich Plasma</keyword>
	<keyword>PRP</keyword>
	<keyword>Hair loss</keyword>
	<keyword>Alopecia</keyword>
	<keyword>Hypotrichosis</keyword>
	<keyword>Hair disease</keyword>
</DOC>